SLS at a glance
SELLAS Life Sciences Group, Inc. (SLS, SEC CIK 1390478) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 20, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2023 (FY2023), SELLAS Life Sciences Group, Inc. (SLS) reported revenue of $0 and a net loss of $37.3 million. Diluted EPS was -$1.34.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding SELLAS Life Sciences Group, Inc. (SLS) shares worth $564.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by CICIC DRAGAN on November 18, 2026 of 6,933 shares at $19.18 per share.
- In the last 90 days, SLS insiders reported 0 open-market purchases ($0) and 3 open-market sales ($717K) on Form 4, a net sale of $717K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2023
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$717K
- 13F holders
- 25 funds
- $564.2M · +2 vs prior quarter
- Latest 8-K
- Nov 20, 2026
- Item 1.01 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes disclosed from the 2025 Annual Report
- Clinical-stage biotechnology risk: Additional unknown risks could materially harm business, financial condition, results, or stock price
- Forward-looking statement risk: Projections remain subject to uncertainties incorporated by reference
- Stock-price risk: Undisclosed or currently immaterial risks could adversely affect valuation
Management Discussion & Analysis
- Revenue $0 from product sales in nine months ended September 30, 2026, unchanged YoY
- Net loss $10.1M vs $6.8M YoY, operating loss $11.3M vs $7.1M
- SLS009 strongest clinical results: 34% ORR all doses, 54% monocytic AML at selected dose
- Cash and equivalents $134.7M plus restricted cash $0.1M, warrant exercises generated $85.1M
- Outlook: cash sufficient for at least twelve months, Phase 2 enrollment ongoing, REGAL topline results expected November 2026
AI summary of the SLS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Equity offering: 11,538,462 shares at $13.00 per share, creating substantial shareholder dilution
- Underwriter 30-day option for 1,730,769 additional shares, potentially increasing dilution
Item 8.01: Other Events
- Underwritten public offering priced November 18, 2026, creating potential equity financing and shareholder dilution
- Exhibit 99.1 contains the offering price, size, and use of proceeds relevant to valuation and liquidity
Item EX-99.1: Item EX-99.1
- $150.0 million gross equity financing through 11,538,462 shares priced at $13.00
- Potential additional dilution from underwriters’ 30-day option for 1,730,769 shares
Item 7.01: Regulation FD Disclosure
- Positive topline results from pivotal randomized Phase 3 REGAL trial of GPS in acute myeloid leukemia
- Potential validation of GPS as an immunotherapeutic cancer vaccine for AML patients
Item 8.01: Other Events
- Phase 3 REGAL met its primary overall-survival endpoint in relapsed/refractory AML
- GPS reduced death risk 41%, hazard ratio 0.59, versus investigator’s-choice best available treatment
Item EX-99.1: Item EX-99.1
- Phase 3 REGAL met its primary endpoint, reducing AML death risk 41% versus best available treatment
- Median overall survival: 24.0 months with GPS versus 14.7 months with BAT, hazard ratio 0.59, p=0.035
Item EX-99.1: Item EX-99.1
- Q3 2026 results and corporate update: primary REGAL endpoint data for GPS expected in November
- REGAL reached the prespecified 80th event, triggering final analysis and unblinding procedures
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Corporate update accompanies results, with substantive details in Exhibit 99.1
AI summaries of SLS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SLS
Don't miss the next SLS filing
- Alerts as it files. A push when SLS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SLS, by share count.
- Ask anything. An AI agent that reads every SLS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| CICIC DRAGAN | Sell | Nov 18, 2026 | 6,933 | $19.18 |
| Burns John Thomas | Sell | Nov 18, 2026 | 3,831 | $19.18 |
| Stergiou Angelos M. | Sell | Nov 18, 2026 | 26,606 | $19.18 |
| Stergiou Angelos M. | A | Jun 16, 2026 | 1,065,000 | - |
| Stergiou Angelos M. | A | Jun 16, 2026 | 1,065,000 | - |
| CICIC DRAGAN | A | Jan 7, 2026 | 300,000 | - |
| Burns John Thomas | A | Jan 7, 2026 | 300,000 | - |
| Varian John | A | Jan 7, 2026 | 50,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $0 | - | - | |
| Operating Income | -$37.9M | -$31.5M | -$28.3M | |
| Net Income | -$37.3M | -$30.9M | -$26.9M | |
| Balance Sheet | ||||
| Total Assets | $6.2M | $19.4M | $78.3M | |
| Equity | -$8.0M | $9.5M | $70.9M | |
| ROE | 468.2% | -326.3% | -37.9% | |
| Per Share | ||||
| EPS | $-1.34 | $-0.50 | $-0.25 | |
| Cash Flow | ||||
| Operating CF | -$31.4M | -$35.4M | -$28.4M | |
Source: XBRL data in SELLAS Life Sciences Group, Inc. (SLS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SLS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $564.2M |
| Q2 2026 | 23 | $666.6M |
| Q1 2026 | 24 | $151.6M |
| Q4 2025 | 19 | $97.3M |
| Q3 2025 | 20 | $28.6M |
| Q2 2025 | 18 | $37.3M |
| Q1 2025 | 10 | $4.4M |
| Q4 2024 | 6 | $3.5M |
- BlackRock+1.11M (+7%)
- Vanguard Capital Management LLC+716.5K (+9%)
- Prudential Financial+714.7K (+2297%)
- Goldman Sachs Group+503.1K (+86%)
- JPMorgan Chase & Co+288.8K (+288%)
- State Street Corp−2.62M (-20%)
- Invesco Ltd−278.2K (-74%)
- Citigroup−207.6K (-64%)
- Wells Fargo & Co−130.7K (-40%)
- Bank of America Corp−51.4K (-7%)
- Raymond James Financial+205.1K
- Ameriprise Financial+92.7K
- First Bancorp, Inc /ME/+2.0K
- U.S. Bancorp+1.3K
- Renaissance Technologies LLC−310.4K
- FMR LLC (Fidelity)−25.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 145 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SLS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 8-K | Nov 20, 2026 | - | Analysis | - |
| 8-K | Nov 17, 2026 | - | Analysis | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 7, 2026 | - | - | |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 10-K | Mar 19, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 19, 2026 | - | Analysis | - |
| 8-K | Mar 11, 2026 | - | Analysis | - |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SLS SEC filings: frequently asked questions
Are SLS insiders buying or selling?
In the last 90 days, SELLAS Life Sciences Group, Inc. (SLS) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $716,682 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SLS stock?
As of September 30, 2026, the largest SELLAS Life Sciences Group, Inc. (SLS) holders among the 13F filers tracked by SignalX were BlackRock ($199.2 million), State Street Corp ($127.7 million), Vanguard Capital Management LLC ($110.1 million), Vanguard Portfolio Management LLC ($28.3 million), Northern Trust ($22.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SLS's revenue in fiscal year 2023?
For the fiscal year ended December 31, 2023 (FY2023), SELLAS Life Sciences Group, Inc. (SLS) reported revenue of $0 and a net loss of $37.3 million. Diluted EPS was -$1.34. The figures come from the XBRL data in the 10-K.
What did SLS report in its latest 8-K?
SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K on November 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 8.01 (Other Events). Equity offering: 11,538,462 shares at $13.00 per share, creating substantial shareholder dilution.
What are the latest SLS SEC filings?
SELLAS Life Sciences Group, Inc. (SLS) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 20, 2026 and a Form 4 insider filing on November 20, 2026.
What is SLS's SEC CIK number?
SELLAS Life Sciences Group, Inc. (SLS)'s SEC Central Index Key (CIK) is 1390478. EDGAR lists every SLS filing under that number.
Ask anything about SLS
The research agent reads SLS's filings, financials, insider trades and 13F holders, then answers with sources.